Satralizumab treatment in patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series
Authors:
Open Access
- 16 March 2025
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 403, 578585
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
- Genentech Inc
This publication has 34 references indexed in Scilit:
- Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSDJournal of Neuroimmunology, 2023
- Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohortJournal of Neurology, 2022
- Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStarMultiple Sclerosis and Related Disorders, 2022
- Symptomatic and restorative therapies in neuromyelitis optica spectrum disordersJournal of Neurology, 2021
- Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorderMultiple Sclerosis and Related Disorders, 2021
- Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysisMultiple Sclerosis and Related Disorders, 2021
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialThe Lancet, 2019
- Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and SymptomaticCurrent Treatment Options in Neurology, 2015
- IL‐6: Regulator of Treg/Th17 balanceEuropean Journal of Immunology, 2010
- Inhibition of Complement as a Therapeutic Approach in Inflammatory Central Nervous System (CNS) DiseaseMolecular Medicine, 1999